Arvinas, Inc. (ARVN) Stock Price & Analysis

Arvinas, Inc. (ARVN) closed at USD 7.6 on Wednesday, October 28, 2026, up 2.01% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 7.45; the Oct 28, 2026 session ranged USD 7.3–7.67 on volume of 891,286 shares. Market capitalization is $490.36M, with a 52-week range of USD 6.74–14.51 (NMS). Source: Nexqual, retrieved October 28, 2026 at 23:47 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ARVN.md

Key facts (ARVN)

• Last four reported quarters (through Jun 30, 2026): revenue $317M, net income $9.3M (2.9% margin), free cash flow -$209M (SEC filings).
• Valuation: P/E 52.7x, net cash $567M.
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $518K; 6 not under a Rule 10b5-1 plan ($452K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.50 on a 1–5 scale) (16 analysts), mean target USD 13.93 (range 6–21).
• Total return with dividends: 1Y -20.8% vs S&P 500 +13.6%; 5Y -91.2% vs S&P 500 +79.8%.
• Next earnings: 2026-11-03, EPS estimate USD -0.95, revenue estimate $16.8M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ARVN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ARVN)

P/E 52.7x · P/S 1.6x · EV/Sales -0.2x · P/B 0.9x · FCF yield -42.58% · Earnings yield 1.90% · Net cash $567M · EV -$77.0M

Insider sales (SEC Form 4, open-market, last ~7 months) (ARVN)

2 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ARVN)

Consensus Hold (mean 2.50 on a 1–5 scale), 16 analysts; mean target USD 13.93 (low 6, high 21).

Rating changes, last 120 days:

Total return (dividends reinvested) (ARVN)

ARVN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ARVN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ARVN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

Companies that name ARVN in their SEC reports

ARVN analyst estimates and revisions

ARVN options: expected move

Options price a move of about ±17.2% (±$1.31) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±8.3% on average.

30-day implied volatility 67.5% vs 53.1% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 23:47 UTC)

Technical Analysis (ARVN)

Nexqual's technical model rates ARVN "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 28, 2026 at 23:47 UTC.

Analyst Ratings (ARVN)

Wall Street analysts rate ARVN "Hold" based on 16 analysts, with a mean price target of USD 13.93 (range USD 6–21), per Nexqual as of October 28, 2026 at 23:47 UTC.

Earnings (ARVN)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 23:47 UTC.

Financials & Fundamentals (ARVN)

Source: Nexqual, October 28, 2026 at 23:47 UTC.

Financial Health Score (ARVN)

Nexqual rates Arvinas, Inc.'s overall financial health "Weak" across five dimensions, as of October 28, 2026 at 23:47 UTC.

Ownership (ARVN)

Source: Nexqual, October 28, 2026 at 23:47 UTC.

Leadership (ARVN)

Arvinas, Inc. is led by Randy Teel, CEO, President & Director, per Nexqual as of October 28, 2026 at 23:47 UTC.

Major Backers & Investors (ARVN)

Notable institutional backers of Arvinas, Inc. include Shaw D.E. & Co., Inc., Pfizer Inc, Armistice Capital, LLC, according to Nexqual as of October 28, 2026 at 23:47 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 23:47 UTC.

From Arvinas, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression.
• We have also created a proprietary software tool to accelerate LEAP library design. •PROTACify: We have built PROTACify, a proprietary computational, machine-learning, or ML, solution for modeling PROTAC ternary complexes to enable selection of the best PROTAC designs for synthesis.
• We believe favorable clinical trial results in our ongoing oncology and neurology programs would further validate our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins.
• With our integrated capabilities we aim to accelerate discovery of TPD therapeutics, translating biological insight into efficient drug design.

Partnerships

• In July 2021, we announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant.
• As part of our global collaboration with Pfizer, we and Pfizer presented patient reported outcomes, or PRO, data from the VERITAC-2 clinical trial in the fourth quarter of 2025 at the European Society for Medical Oncology, or ESMO, 2025 Congress.

Legal & Regulatory Risks (Item 1A, quoted)

• Our expenses could increase beyond our expectations if we are required by the FDA, the EMA, or other regulatory authorities to perform trials in addition to those that we currently expect or anticipate, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our current or future product candidates.
• Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.
• Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
• Changes in patent laws or patent jurisprudence could diminish the value of our patents in general, thereby impairing our ability to protect our product candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 23:47 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt